Skip to main content

Vor Biopharma Inc.

VOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001817229

No open-market purchases or sales by Vor Biopharma Inc. insiders were filed in the last 90 days; 155 institutions reported holding it in 13F filings for Q3 2026, worth $1.06B in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 31, 2026, 1:14 AM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of Vor Biopharma Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 12, 2026––––
Operating expenses$371.6M$121.2M$126.0M$93.4M$69.0M
Research and development$321.5M$93.3M$94.3M$64.5M$47.5M
Selling, general and administrative$50.1M$27.9M$31.7M$28.9M$21.5M
Operating income-$371.6M-$121.2M-$126.0M-$93.4M-$69.0M
Net income-$696.0M-$116.9M-$117.9M-$92.1M-$68.9M
EPS, basic$-70.50$-1.70$-1.75$-2.33–
EPS, diluted$-70.50$-1.70$-1.75$-2.33–
Weighted shares, basic9.87M68.7M67.2M39.6M–
Weighted shares, diluted9.87M68.7M67.2M39.6M–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Vor Biopharma Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 12, 2026––––
Cash and equivalents$396.5M$81.9M$31.4M$57.7M$119.8M
Short-term investments$58.7M$9.98M$105.8M$172.5M$87.7M
Total current assets$458.1M$96.5M$140.8M$236.9M$214.4M
Property, plant and equipment$533.0K$6.58M$10.1M$12.6M$6.85M
Total assets$464.1M$142.9M$198.1M$299.4M$242.6M
Accounts payable$5.13M$1.50M$815.0K$1.77M$1.54M
Total current liabilities$25.2M$18.6M$15.6M$13.1M$10.2M
Total liabilities$628.4M$46.2M$47.4M$48.8M$26.3M
Shareholders' equity-$164.3M$96.7M$150.7M$250.6M$216.3M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Vor Biopharma Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 12, 2026––––
Operating cash flow-$142.7M-$99.7M-$100.3M-$85.1M-$69.1M
Capital expenditures$941.0K$229.0K$1.07M$8.46M$3.89M
Free cash flow-$143.7M-$99.9M-$101.4M-$93.6M-$73.0M
Stock-based compensation$18.9M$9.85M$13.4M$10.7M$4.32M
Dividends paid$0$0$0$0$0
Investing cash flow-$48.8M$96.9M$71.0M-$94.1M-$91.7M
Financing cash flow$503.8M$53.4M$2.94M$117.1M$232.9M
Net change in cash$312.3M$50.6M-$26.3M-$62.1M$72.1M

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Vor Biopharma Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Oct 26, 202661.4M+490.1%SEC
Aug 6, 202659.2M−53.3%SEC
May 7, 202654.2M−56.6%SEC
Mar 23, 202648.8M−60.9%SEC
Nov 7, 202510.4M−84.8%SEC
Aug 6, 2025126.7M+85.2%SEC
May 8, 2025125.0M+83.1%SEC
Mar 13, 2025124.9M+83.2%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-20 in Q3 2025.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.